最新更新 :
08/05/2024
細胞増殖抑制薬   Vinblastine sulfate  
注射薬
溶媒内の安定性 混合時の安定性 安定性に影響する因子 互換性 投与経路 引用文献 PDF
   化学構造  

商品名   商品名     

商品名、賦形剤は国、製薬会社ごとに異なることがあります

Blestinib メキシコ
Cytoblastin エジプト, マレーシア
Lemblastine コロンビア, チリ, メキシコ
Oncoblastin コロンビア
Uniblastin ペルー
VBlastin インド
Velbe アラブ首長国連邦, アーストラリア, イギリス, イタリア, オランダ, オーストリア, ギリシア, サウジアラビア, スイス, スウェーデン, チリ, デンマーク, ノルウェー, フィンランド, フランス, モロッコ, ルクセンブルグ
Velblastin エジプト, マレーシア
Vinblasine ルクセンブルグ
Vinblastin ハンガリー, ポーランド
Vinblastina アルゼンチン, エクアドル, コロンビア, スペイン, チリ, ペルー, メキシコ, ルーマニア
Vinblastine アイルランド, アメリカ, アーストラリア, イギリス, イラン, オランダ, カナダ, サウジアラビア, チュニジア, ニュージーランド, フランス, ベルギー
Vinblastinsulfat ドイツ
Vinblatine マレーシア
Vinko トルコ
引用文献   注射薬   引用文献 : Vinblastine sulfate  
形式 出版物
3 雑誌 Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
81 雑誌 Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678.
84 雑誌 Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499.
99 雑誌 Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
144 雑誌 Dine T, Luyckx M, Cazin JC, Goudaliez F, Mallevais ML.
Stability and compatibility studies of vinblastine, vincristine, vindesine and vinorelbine with PVC infusion bags.
Int J Pharm 1991 ; 77: 279-285.
167 雑誌 Francomb MM, Ford JL, Lee MG.
Adsorption of vincristine, vinblastine, doxorubicin and mitoxantrone to in-line intravenous filters.
Int J Pharm 1994 ; 103: 87-92.
169 雑誌 Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363.
182 雑誌 Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60.
244 雑誌 Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913.
248 雑誌 Trissel LA, Martinez JF.
Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection.
Am J Hosp Pharm 1993 ; 50: 300-304.
249 雑誌 Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251 雑誌 Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
307 雑誌 Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799.
334 雑誌 Trissel LA, Tramonte SM, Grilley BJ.
Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 988-992.
335 雑誌 Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406.
481 雑誌 Beijnen JH, Vendrig DEMM, Underberg WJM.
Stability of vinca alkaloid anticancer drugs in three commonly used infusion fluids.
J Parenter Sci Technol 1989 ; 43: 84-87.
492 雑誌 Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189.
763 雑誌 Cohen MH, Jonhson-Early A, Hood MA, McKenzie M, Citron ML, Jaffe N, Krasnow SH.
Drug precipitation within IV tubing : A potential hazard of chemotherapy administration.
Cancer Treat Rep 1985 ; 69: 1325-1326.
827 雑誌 Black J, Buechter DD, Thurston DE.
Stability of vinblastine sulfate when exposed to light.
Drug Intell Clin Pharm 1988 ; 22: 634-636.
905 雑誌 Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017.
921 雑誌 Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292.
1009 雑誌 Black J, Buechter DD, Chinn JW, Gard J, Thurston DE.
Studies on the stability of vinblastine sulfate in aqueous solution.
J Pharm Sci 1988 ; 77: 630-634.
1157 雑誌 Vendrig DEMM, Smeets BPGM, Beijnen JH, van der Houwen OAGJ, Holthuis JJM.
Degradation kinetics of vinblastine sulphate in aqueous solutions.
Int J Pharm 1988 ; 43: 131-138.
1229 雑誌 Weir PJ, Ireland DS.
Chemical stability of cytarabine and vinblastine injections.
Br J Pharm Pract 1990 ; 12: 53-54, 60.
1410 雑誌 Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1423 雑誌 Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
1625 雑誌 Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321.
1727 雑誌 Mittner A, Vincze Z, Jemnitz K.
Stability of vinblastine sulphate containing infusions.
Pharmazie 1999 ; 54: 625-626.
1953 雑誌 Trissel LA, Saenz CA, Ogundele AB, Ingram DS.
Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
3540 実験 Heparin sodium - Summary of Product Characteristics.
Wockhardt 2010
3578 実験 Cisplatin - Summary of Product Characteristics
Accord Healthcare 2011
3644 実験 Calcium gluconate® - Summary of Product Characteristics
Hameln Pharmaceuticals 2010

  Mentions Légales